platinum has been researched along with Minimal Disease, Residual in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bulleri, A; Cosio, S; Frey, J; Gadducci, A; Mezzapesa, F; Miccoli, M; Neri, E; Simonetti, E; Tintori, R | 1 |
| Ferrari, F; Gadducci, A; Landoni, F; Peiretti, M; Perrone, F; Sartori, E; Tana, R | 1 |
| Achatz, MI; Baiocchi, G; da Costa, AA; Guimarães, AP; Mantoan, H; Saito, A; Sanches, S; Valadares, CV | 1 |
| Altınbaş, SK; Boran, N; Celik, B; Hızlı, D; Köse, MF; Turan, T; Yılmaz, S | 1 |
| Horwich, A; Stenning, S | 1 |
| Fujiwara, K | 1 |
1 trial(s) available for platinum and Minimal Disease, Residual
| Article | Year |
|---|---|
Initial chemotherapy for stage II testicular non-seminoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confidence Intervals; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Staging; Neoplasm, Residual; Norway; Orchiectomy; Platinum; Prognosis; Remission Induction; Retroperitoneal Neoplasms; Retrospective Studies; Survival Rate; Teratoma; Testicular Neoplasms; United Kingdom | 1994 |
5 other study(ies) available for platinum and Minimal Disease, Residual
| Article | Year |
|---|---|
Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Ovarian Cancer Treated With Primary Surgery Followed by Platinum-based Chemotherapy: A Single-center Italian Study.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Italy; Middle Aged; Muscle, Skeletal; Neoplasm, Residual; Ovarian Neoplasms; Ovariectomy; Platinum; Prognosis; Progression-Free Survival; Retrospective Studies; Sarcopenia; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2022 |
Analysis of failures and clinical outcome of advanced epithelial ovarian cancer in patients with microscopic residual disease at second-look reassessment following primary cytoreductive surgery and first-line platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Retrospective Studies; Second-Look Surgery; Treatment Failure; Treatment Outcome | 2013 |
Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Risk Factors; Survival Rate | 2015 |
Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Intraperitoneal chemotherapy and intraperitoneal washing cytology in management of ovarian cancer.
Topics: Antineoplastic Agents; Carboplatin; Female; Humans; Infusions, Parenteral; Neoplasm, Residual; Ovarian Neoplasms; Peritoneal Lavage; Platinum; Reoperation; Survival Analysis | 2000 |